Scientific advances are benefiting cancer patients, but it will take a pandemic-like response to ensure patients everywhere have access.
Robert LaCaze
Advertisement
Member of the Executive Committee of Bayer AG’s Pharmaceuticals Division and Head of the Oncology Strategic Business Unit
Articles by Robert LaCaze
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Bayer’s Lynkuet as First Dual Neurokinin Antagonist for Menopausal Hot Flashes
2
Direct-to-patient: pharma’s next power move
3
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
4
AI Becomes Pharma’s New Operating System: Q&A with causaLens’ CEO and Co-Founder Darko Matovski
5
